We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy.
- Authors
Yaiw, K-C; Miest, T S; Frenzke, M; Timm, M; Johnston, P B; Cattaneo, R
- Abstract
New therapeutic modalities for B-cell non-Hodgkin's lymphomas (B-NHL) are needed, especially for relapsing and aggressive subtypes. Toward this end, we previously generated a fully CD20-targeted and armed measles virus, and tested its efficacy in a xenograft model of mantle cell lymphoma (MCL). Here, we quantify its spread in peripheral blood mononuclear cells and/or tissue of patients with different histological subtypes of B-NHL, including splenic marginal zone lymphoma (SMZL). CD20-targeted MV efficiently infects lymphoma cells from SMZL and MCL while sparing most cells in the CD20-negative population, in contrast to the parental vaccine-lineage MV, which infects CD20-positive and CD20-negative cells equally. Rituximab therapy (4-8 months before relapse) did not interfere with the infectivity and specificity of MVgreenHblindantiCD20 in patient lymphoma samples. Thus, CD20-targeted oncolytic virotherapy is likely to be effective after previous antiCD20 therapy.
- Subjects
MEASLES virus; LYMPHOMA treatment; RITUXIMAB; B cells; XENOGRAFTS; CANCER relapse; GENE therapy; PREVENTION
- Publication
Gene Therapy, 2011, Vol 18, Issue 3, p313
- ISSN
0969-7128
- Publication type
Article
- DOI
10.1038/gt.2010.150